NEW YORK, January 25, 2023 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has selected 3 of its clinical sites for its Phase 2a clinical trial for the treatment of rashes and skin disorders associated with epidermal growth factor receptor inhibitor therapy. (EGFR). EGFR inhibitors are critical therapeutic agents for the treatment of non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, head and neck squamous cell carcinoma, and breast cancer. Phase 2a dose ranging study as well as a proposed follow-up phase 2b dose extension study of safety and efficacy; both studies will be conducted in cancer patients receiving EGFR inhibitor therapy.).
The 3 initial clinical sites for Phase 2a are located in the United States in the following cities:
St Louis, Missouri
“We are pleased to have selected our initial clinical sites,” said Robb Knie, Chief Executive Officer of the Company. “The caliber of clinics selected represent some of the best cancer care facilities in the country. This selection process represents an important milestone for Hoth and we look forward to beginning patient enrollment.”
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing breakthrough, impactful, and innovative treatments with the goal of improving patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, taking drugs from the bench to preclinical and clinical trials. Using a patient-centric approach, we collaborate and partner with a team of leading scientists, clinicians and thought leaders to seek out and investigate therapies that have immense potential to advance and diversify treatment options. To learn more, visit https://ir.hoththerapeutics.com/.
Statement of Forecast
This press release includes forward-looking statements based on Hoth’s current expectations, which may constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to to substantial risks, uncertainties and assumptions, including, but not limited to, market and other conditions. These statements relate to the intended use of the net proceeds of the private placement, Hoth’s business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates Hoth may develop, and labeling under any approvals Hoth may obtain; the schedule and costs of clinical trials, the schedule and costs of other expenses; market acceptance of Hoth’s products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on Hoth’s business, its clinical trials, its research programs, health systems or the global economy as a whole; Hoth’s intellectual property; Hoth’s reliance on third-party organizations; Hoth’s competitive position; industrial environment of Hoth; Hoth’s anticipated financial and operating results, including anticipated sources of revenue; Hoth’s assumptions regarding available market size, benefits of Hoth’s products, product pricing, timing of product launches; management’s expectations regarding future acquisitions; statements about Hoth’s objectives, intentions, plans and expectations, including the introduction of new products and markets; and Hoth’s cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place undue reliance on these forward-looking statements, which include words such as “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “anticipate”, “potential”, “project” or similar terms, variations of such terms or the negative of such terms. Although Hoth believes that the expectations reflected in the forward-looking statements are reasonable, Hoth cannot guarantee such results. Hoth may not fulfill your expectations and your beliefs may not be correct. Actual results could differ materially from those indicated by these forward-looking statements as a result of a number of important factors, including, without limitation, market conditions and the factors described in the section entitled “Risk Factors” in Hoth’s most recent Annual Report on Form 10 – K and other Hoth filings filed with the US Securities and Exchange Commission. All such statements speak only as of the date of this press release. Accordingly, the forward-looking statements should be considered only as Hoth’s current plans, estimates and beliefs. Hoth cannot guarantee future results, events, activity levels, performance or achievements. Hoth specifically disclaims and disclaims any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrence of unforeseen events, except as required by applicable law.
LR Advisors LLC
Email: [email protected]
Phone: (678) 570-6791
See original content for multimedia download: https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-selection-of-first-3-clinical-sites-for-its-phase-2-clinical- trial-to-treat-epidermal-growth-factor-receptor-associated-cancer-disorders-egfr-inhibitor-therapy-301730165.html
SOURCE Hoth Therapeutics, Inc.